Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears This biotech innovator in antibody therapies for IBD reported a notable insider sale amid ongoing preclinical development efforts.
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.
VR Adviser Adds Over 1 Million Savara Shares This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Spyre Therapeutics' CEO Sells 15,000 Shares This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing.
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
